BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32406600)

  • 21. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis.
    Takane K; Matsusaka K; Ota S; Fukuyo M; Yue Y; Nishimura M; Sakai E; Matsushita K; Miyauchi H; Aburatani H; Nakatani Y; Takayama T; Matsubara H; Akagi K; Kaneda A
    Oncotarget; 2016 Dec; 7(51):84003-84016. PubMed ID: 27563825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.
    Cheng PF; Shakhova O; Widmer DS; Eichhoff OM; Zingg D; Frommel SC; Belloni B; Raaijmakers MI; Goldinger SM; Santoro R; Hemmi S; Sommer L; Dummer R; Levesque MP
    Genome Biol; 2015 Feb; 16(1):42. PubMed ID: 25885555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA methylation characteristics of primary melanomas with distinct biological behaviour.
    Ecsedi S; Hernandez-Vargas H; Lima SC; Vizkeleti L; Toth R; Lazar V; Koroknai V; Kiss T; Emri G; Herceg Z; Adany R; Balazs M
    PLoS One; 2014; 9(5):e96612. PubMed ID: 24832207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma.
    Liu D; Liu X; Xing M
    Biochem Biophys Res Commun; 2012 Aug; 425(1):45-50. PubMed ID: 22820187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.
    Hata A; Nakajima T; Matsusaka K; Fukuyo M; Morimoto J; Yamamoto T; Sakairi Y; Rahmutulla B; Ota S; Wada H; Suzuki H; Matsubara H; Yoshino I; Kaneda A
    Int J Cancer; 2020 Jan; 146(2):388-399. PubMed ID: 31241180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
    Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
    Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic biomarkers in skin cancer.
    Greenberg ES; Chong KK; Huynh KT; Tanaka R; Hoon DS
    Cancer Lett; 2014 Jan; 342(2):170-7. PubMed ID: 22289720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological relevance of BRAF mutations in human cancer.
    Pakneshan S; Salajegheh A; Smith RA; Lam AK
    Pathology; 2013 Jun; 45(4):346-56. PubMed ID: 23594689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
    Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
    [No Abstract]   [Full Text] [Related]  

  • 33. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
    Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.
    Jonsson A; Tuominen R; Grafström E; Hansson J; Egyhazi S
    J Invest Dermatol; 2010 Dec; 130(12):2809-17. PubMed ID: 20703244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated differential DNA methylation and gene expression of formalin-fixed paraffin-embedded uveal melanoma specimens identifies genes associated with early metastasis and poor prognosis.
    Ness C; Katta K; Garred Ø; Kumar T; Olstad OK; Petrovski G; Moe MC; Noer A
    Exp Eye Res; 2021 Feb; 203():108426. PubMed ID: 33387485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
    Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
    Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
    Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
    Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
    Guo X; Xu Y; Zhao Z
    Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
    Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
    Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
    Mezzanotte JJ; Hill V; Schmidt ML; Shinawi T; Tommasi S; Krex D; Schackert G; Pfeifer GP; Latif F; Clark GJ
    Epigenetics; 2014 Nov; 9(11):1496-503. PubMed ID: 25482183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.